Skip to main content

Table 3 Expression analysis of genes involved in base-excision repair

From: The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)

  APE1
Median (range)
PARP1
Median (range)
XRCC1
Median (range)
Stable disease/Partial response
(n = 7)
32.45 (0.01–176.7) 0.5 (0.001–2.63) 0.2 (0.008–1.05)
Progression
(n = 7)
47.18 (4.48–87.73) 1.36 (0.01–26.17) 0.58 (0.04–1.26)
  1. Data are expressed as relative log2 expression